ReviewFrontiers in oncology2026
The Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cancer epitopes, the molecular structures recognized by T and B cells at the tumor interface, are central to understanding antitumor immunity and developing immunotherapies. Yet despite the rapid growth of cancer immunology data, a comprehensive, continuously updated, and accessible resource for cancer epitope data has been lacking. The Cancer Epitope Database and Analysis Resource (CEDAR, cedar.iedb.org) was established in 2021 to fill this gap, providing curated experimental epitope data alongside a suite of cancer-specific computational tools for epitope prediction and analysis. Built on the validated infrastructure of the Immune Epitope Database (IEDB), CEDAR integrates cancer epitope data with biological, immunological, and clinical context, enabling researchers to explore immune recognition of tumors, identify candidate targets for immunotherapy, and benchmark prediction methods. Here we describe CEDAR's current capabilities, report on progress in curation, database development, and tool availability, and outline the opportunities and challenges ahead for expanding its scope and utility to the cancer research community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.